CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives

Mohamad Mohty; Jordan Gautier; Florent Malard; Mahmoud Aljurf; Ali Bazarbachi; Christian Chabannon; Mohamed A. Kharfan-Dabaja; Bipin N. Savani; He Huang; Saad Kenderian; Arnon Nagler; Miguel Angel Perales

doi:10.1038/s41375-019-0615-5

CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives

Mohamad Mohty, Jordan Gautier, Florent Malard, Mahmoud Aljurf, Ali Bazarbachi, Christian Chabannon, Mohamed A. Kharfan-Dabaja, Bipin N. Savani, He Huang, Saad Kenderian, Arnon Nagler, Miguel Angel Perales

Hematology

Research output: Contribution to journal › Review article › peer-review

25 Scopus citations

Abstract

The approval of tisagenlecleucel and axicabtagene ciloleucel represents a breakthrough in the field of immune and cellular therapy for hematologic malignancies. These anti-CD19 chimeric antigen receptor-T cells (CAR) proved to be highly effective in the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) and specific histologic subtypes of B-cell non-Hodgkin lymphomas. This expert review aims to summarize the current available research evidence in this field, with a special focus on the different challenges faced by treating physicians, and we also provide future perspectives.

Original language	English (US)
Pages (from-to)	2767-2778
Number of pages	12
Journal	Leukemia
Volume	33
Issue number	12
DOIs	https://doi.org/10.1038/s41375-019-0615-5
State	Published - Dec 1 2019

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1038/s41375-019-0615-5

Cite this

CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma : current status and perspectives. / Mohty, Mohamad; Gautier, Jordan; Malard, Florent; Aljurf, Mahmoud; Bazarbachi, Ali; Chabannon, Christian; Kharfan-Dabaja, Mohamed A.; Savani, Bipin N.; Huang, He; Kenderian, Saad; Nagler, Arnon; Perales, Miguel Angel.

In: Leukemia, Vol. 33, No. 12, 01.12.2019, p. 2767-2778.

Research output: Contribution to journal › Review article › peer-review

Mohty, Mohamad ; Gautier, Jordan ; Malard, Florent ; Aljurf, Mahmoud ; Bazarbachi, Ali ; Chabannon, Christian ; Kharfan-Dabaja, Mohamed A. ; Savani, Bipin N. ; Huang, He ; Kenderian, Saad ; Nagler, Arnon ; Perales, Miguel Angel. / CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma : current status and perspectives. In: Leukemia. 2019 ; Vol. 33, No. 12. pp. 2767-2778.

@article{b99cd4b7717e47c3b08d8eb271ed6300,

title = "CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives",

abstract = "The approval of tisagenlecleucel and axicabtagene ciloleucel represents a breakthrough in the field of immune and cellular therapy for hematologic malignancies. These anti-CD19 chimeric antigen receptor-T cells (CAR) proved to be highly effective in the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) and specific histologic subtypes of B-cell non-Hodgkin lymphomas. This expert review aims to summarize the current available research evidence in this field, with a special focus on the different challenges faced by treating physicians, and we also provide future perspectives.",

author = "Mohamad Mohty and Jordan Gautier and Florent Malard and Mahmoud Aljurf and Ali Bazarbachi and Christian Chabannon and Kharfan-Dabaja, {Mohamed A.} and Savani, {Bipin N.} and He Huang and Saad Kenderian and Arnon Nagler and Perales, {Miguel Angel}",

note = "Publisher Copyright: {\textcopyright} 2019, The Author(s), under exclusive licence to Springer Nature Limited.",

year = "2019",

month = dec,

day = "1",

doi = "10.1038/s41375-019-0615-5",

language = "English (US)",

volume = "33",

pages = "2767--2778",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Nature Publishing Group",

number = "12",

}

TY - JOUR

T1 - CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma

T2 - current status and perspectives

AU - Mohty, Mohamad

AU - Gautier, Jordan

AU - Malard, Florent

AU - Aljurf, Mahmoud

AU - Bazarbachi, Ali

AU - Chabannon, Christian

AU - Kharfan-Dabaja, Mohamed A.

AU - Savani, Bipin N.

AU - Huang, He

AU - Kenderian, Saad

AU - Nagler, Arnon

AU - Perales, Miguel Angel

PY - 2019/12/1

Y1 - 2019/12/1

N2 - The approval of tisagenlecleucel and axicabtagene ciloleucel represents a breakthrough in the field of immune and cellular therapy for hematologic malignancies. These anti-CD19 chimeric antigen receptor-T cells (CAR) proved to be highly effective in the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) and specific histologic subtypes of B-cell non-Hodgkin lymphomas. This expert review aims to summarize the current available research evidence in this field, with a special focus on the different challenges faced by treating physicians, and we also provide future perspectives.

AB - The approval of tisagenlecleucel and axicabtagene ciloleucel represents a breakthrough in the field of immune and cellular therapy for hematologic malignancies. These anti-CD19 chimeric antigen receptor-T cells (CAR) proved to be highly effective in the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) and specific histologic subtypes of B-cell non-Hodgkin lymphomas. This expert review aims to summarize the current available research evidence in this field, with a special focus on the different challenges faced by treating physicians, and we also provide future perspectives.

UR - http://www.scopus.com/inward/record.url?scp=85074800931&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074800931&partnerID=8YFLogxK

U2 - 10.1038/s41375-019-0615-5

DO - 10.1038/s41375-019-0615-5

M3 - Review article

C2 - 31690821

AN - SCOPUS:85074800931

VL - 33

SP - 2767

EP - 2778

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 12

ER -

CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this